What steps are being taken by ICMR to treat sickle cell disease in children
ICMR seeks to provide oral formulation of hydroxyurea to treat sickle cell disease in children.
- ICMR is conducting studies to assess the safety and efficacy of hydroxyurea in children with sickle cell disease.
- They are developing an oral formulation of hydroxyurea specifically for children, to make the treatment more accessible and effective.
- ICMR is collaborating with pharmaceutical companies for the production and distribution of the oral formulation.
- They are organizing awareness programs and training sessions for healthcare providers to ensure proper use of hydroxyurea in children.
- ICMR is also involved in monitoring and evaluation of the treatment outcomes to continuously improve the management of sickle cell disease in children.
Answered
a year ago